Market Research Logo

Octapharma AG - Strategic SWOT Analysis Review

Octapharma AG - Strategic SWOT Analysis Review

Octapharma AG - Strategic SWOT Analysis Review

- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Octapharma AG (Octapharma) is a human protein manufacturer that focuses on developing and producing human proteins from human plasma and cell lines. The company treats patients worldwide with products across haematology (coagulation disorders), immunotherapy (immune disorders) and critical care therapeutic areas. It sources majority of plasma from company-owned donation centers. Octapharma owns plasma donation centers in the USA and in Germany, and owns six state-of-the-art production facilities in Austria, Germany, France, Mexico and Sweden. The company’s production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labelling, packaging, storage and distribution. Octapharma is headquartered in Lachen, Switzerland.
Octapharma AG Key Recent Developments

May 28,2018: Octapharma present new data on the benefits of Nuwiq in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Mar 01,2018: Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million
Mar 01,2017: Octapharma Group Publishes 2016 Annual Results Reporting Revenue of €1.6 Billion and Operating Income of €383 Million

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.


Section 1 - About the Company
Octapharma AG - Key Facts
Octapharma AG - Key Employees
Octapharma AG - Major Products and Services
Octapharma AG - History
Octapharma AG - Company Statement
Octapharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Octapharma AG - Business Description
Octapharma AG - Corporate Strategy
Octapharma AG - SWOT Analysis
SWOT Analysis - Overview
Octapharma AG - Strengths
Octapharma AG - Weaknesses
Octapharma AG - Opportunities
Octapharma AG - Threats
Octapharma AG - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Octapharma AG, Recent Deals Summary
Section 4 – Company’s Recent Developments
May 28, 2018: Octapharma present new data on the benefits of Nuwiq in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Mar 01, 2018: Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million
Mar 01, 2017: Octapharma Group Publishes 2016 Annual Results Reporting Revenue of €1.6 Billion and Operating Income of €383 Million
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Octapharma AG, Key Facts
Octapharma AG, Key Employees
Octapharma AG, Major Products and Services
Octapharma AG, History
Octapharma AG, Other Locations
Octapharma AG, Subsidiaries
Octapharma AG, Key Competitors
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Octapharma AG, Recent Deals Summary
List of Figures
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Octapharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report